Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9837-9845

  Contag, Christopher H ^a   Sikorski, Rachel ^c   Negrin, Robert S ^b   Schmidt, Tobi ^a   Fan, Alice C ^b   Bachireddy, Pavan ^b   Felsher, Dean W ^b   Thorne, Steve H ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL THERAPY; DISEASE FREE INTERVAL; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LYMPHATIC SYSTEM; LYMPHOMA; LYMPHOMA CELL; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; TUMOR IMMUNITY;

ANIMALS; HUMANS; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; NEOPLASM, RESIDUAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTO-ONCOGENE PROTEINS C-MYC; TISSUE THERAPY; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 78649926094     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2650     Document Type: Article

References (19)

1. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006;311:1780-4.
2. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687-96.
3. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:181-7. (Pubitemid 40287916)
4. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007;117:3350-8.
5. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71.
6. McCart JA, Ward JM, Lee J, Hu Y, Alexaendar HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7. (Pubitemid 34013887)
7. Thorne SH, Contag CH. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther 2008;15:753-8.
8. Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet 2008;4:e1000090. (Pubitemid 351914817)
9. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
10. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006;103:16266-71.
11. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007;104: 13028-33. (Pubitemid 351737587)
12. Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, et al. Combined inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One 2008;3: e2125.
13. Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 2008;68: 5132-42.
14. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003;101:2797-803. (Pubitemid 36857646)
15. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graftversus- host disease induction due to interferon gamma production. Blood 2001;97:2923-31.
16. Cao YA, Bachmann MH, Beilhack A, Yang Y, Tanaka M, Swijnenburg RJ, et al. Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation 2005;80:134-9.
17. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003;9:1377-82. (Pubitemid 37466186)
18. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003;101:640-8. (Pubitemid 36077588)
19. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009;154374-81.